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Abstract
Background and Objective Gentamicin is an aminoglycoside antibiotic predominantly used in bloodstream infections. 
Although the prevalence of obesity is increasing dramatically, there is no consensus on how to adjust the dose in obese indi-
viduals. In this prospective clinical study, we study the pharmacokinetics of gentamicin in morbidly obese and non-obese 
individuals to develop a dosing algorithm that results in adequate drug exposure across body weights.
Methods Morbidly obese subjects undergoing bariatric surgery and non-obese healthy volunteers received one intravenous 
dose of gentamicin (obese: 5 mg/kg based on lean body weight, non-obese: 5 mg/kg based on total body weight [TBW]) 
with subsequent 24-h sampling. All individuals had a normal renal function. Statistical analysis, modelling and Monte Carlo 
simulations were performed using R version 3.4.4 and  NONMEM® version 7.3.
Results A two-compartment model best described the data. TBW was the best predictor for both clearance [CL = 
0.089 × (TBW/70)0.73] and central volume of distribution [Vc = 11.9 × (TBW/70)1.25] (both p < 0.001). Simulations showed 
how gentamicin exposure changes across the weight range with currently used dosing algorithms and illustrated that using 
a nomogram based on a ‘dose weight’ [70 × (TBW/70)0.73] will lead to similar exposure across the entire population.
Conclusions In this study in morbidly obese and non-obese individuals ranging from 53 to 221 kg we identified body weight 
as an important determinant for both gentamicin CL and Vc. Using a body weight-based dosing algorithm, optimized exposure 
across the entire population can be achieved, thereby potentially improving efficacy and safety of gentamicin in the obese 
and morbidly obese population.
Trial Registration Registered in the Dutch Trial Registry (NTR6058).
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 2-019-00762 -4) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Gentamicin is an aminoglycoside antibiotic that is frequently 
used in severe life-threatening infections. Aminoglycosides 
are widely used antibiotics, predominantly used empiri-
cally to expand Gram-negative coverage, although emerg-
ing aminoglycoside resistance is a widely recognized threat 
[1]. Clearly, a favorable outcome can only be achieved with 
gentamicin if adequate exposure is ensured. For aminoglyco-
sides, a distinct relation between aminoglycoside blood con-
centrations and both efficacy and toxicity has been reported 
[2]. Many studies, mostly in vitro and animal in vivo studies, 
have shown that both the gentamicin maximum (peak) con-
centrations (Cmax) relative to the minimal inhibitory concen-
tration (MIC) (Cmax/MIC) and the 24-h free drug area under 
the concentration–time curve (fAUC 24)/MIC is predictive for 
effectiveness [3–5]. While these pharmacodynamic indices 
are to some extent correlated, the general consensus now is 
that fAUC 24/MIC is the primary pharmacodynamic index 
for aminoglycosides driving efficacy [2, 6, 7]. Aminogly-
coside (nephro- and oto-) toxicity correlates with minimum 
(trough) concentrations (Cmin) > 1 mg/L [8].
Obesity and morbid obesity, commonly defined as a body 
mass index (BMI) of >  40 kg/m2, is known to influence 
different pharmacokinetic parameters such as clearance and 
1334 C. Smit et al.
Key Points 
There is currently no consensus on how gentamicin 
should be dosed in obese and morbidly obese individu-
als.
In this study with 20 morbidly obese individuals and 
eight non-obese individuals with body weights from 
53 to 221 kg and normal renal function, we found that 
body weight is an important determinant of gentamicin 
clearance and central volume of distribution in a two-
compartmental model.
We introduce a novel dose regimen to be used in obese 
patients with a normal renal function, which is based on 
an allometric ‘dose weight’ [calculated as 70 × (total 
body weight/70)0.73] to obtain similar exposure across all 
body weights up to 215 kg.
In this prospective clinical study, we study the pharma-
cokinetics of gentamicin in obese and morbidly obese indi-
viduals versus non-obese individuals in order to develop a 
dosing algorithm that can be used across the whole clinical 
population, and that will lead to similar exposure (area under 
the concentration–time curve from time zero to 24 h [AUC 
24]) and optimal Cmin values (< 1 mg/L) in obese individuals 
compared with their non-obese counterparts.
2  Patients and Methods
2.1  Participants
Morbidly obese patients (BMI above 40 kg/m2 or above 
35 kg/m2 with co-morbidities) scheduled to undergo lapa-
roscopic bariatric surgery (either a gastric bypass or sleeve 
gastrectomy) and non-obese healthy volunteers (BMI 
18–25 kg/m2) were considered for inclusion in this study. 
Exclusion criteria were a known allergy to aminoglycosides, 
renal insufficiency (defined as an estimated glomerular filtra-
tion rate [eGFR] below 60 mL/min based on the Cockcroft-
Gault [CG] formula with LBW and the Modification of Diet 
in Renal Disease [MDRD] formula for obese and non-obese 
individuals, respectively) [18–20], pregnancy or breastfeed-
ing, or treatment with potentially nephrotoxic medication 
in the week before surgery. Before inclusion, participants 
provided written informed consent. The study was registered 
in the Dutch Trial Registry (NTR6058), approved by the 
local human research and ethics committee, and was con-
ducted in accordance with the principles of the Declaration 
of Helsinki.
2.2  Study Procedures and Data Collection
Morbidly obese patients received a single gentamicin dose 
of 5 mg/kg LBW (calculated using the Janmahasatian for-
mula [18]), administered intravenously in 30 min, 1–2 h 
prior to induction of anesthesia. We chose a LBW-based 
dose regimen for obese individuals because the use of total 
body weight (TBW) was expected to lead to very high doses 
and because LBW may be a good body size descriptor for 
gentamicin dosing [17]. Gentamicin was administered as 
part of the study protocol, not as part of routine care. Non-
obese healthy volunteers received a dose of 5 mg/kg TBW 
infused over 30 min. Venous blood samples were collected 
5, 30, 60, 90, 120, 180, 240, 360, 720, and 1440 min after 
end of infusion. Blood samples (3 mL) were collected in 
lithium-heparin tubes, centrifuged at 1900g for 5 min, and 
stored at − 80 °C until analysis.
For each patient, data were recorded on body weight, 
body length, sex, age, and self-reported history/duration of 
obesity (estimation of number of years the patient fulfils 
volume of distribution, even though exact quantification is 
still warranted for many drugs [9, 10]. This is especially 
true for gentamicin, which in normal weight patients is typi-
cally dosed on a mg/kg basis [11]. For obese individuals, 
several dosing strategies have been proposed, mostly based 
on alternative body size descriptors such as adjusted body 
weight (ABW). ABW uses a scaling factor for correcting for 
limited drug diffusion in adipose body tissue [12]. Several 
studies found that with increasing body weight, ABW was 
predictive for changes in aminoglycoside volume of distri-
bution [12–16] and therefore for Cmax. More recently, lean 
body weight (LBW; represents fat-free mass consisting of 
bone tissue, muscles, organs, and blood volume calculated 
according to the Janmahasatian formula) was suggested for 
use in dosing gentamicin, also because of its correlation with 
volume of distribution [17, 18]. However, as gentamicin 
exposure drives efficacy, changes in gentamicin clearance 
are to be taken into account when optimizing drug dosing 
in the obese. Previous studies report an increase in total 
body clearance with increasing body weight [12–14, 16], 
with two studies suggesting that ABW might be a predic-
tive covariate for gentamicin clearance [13, 14]. However, 
compared to current practice, the degree of obesity in these 
studies was limited, with average body weights that do not 
exceed 100 kg in most studies. Moreover, many studies rely 
on sparse sampling from therapeutic drug monitoring, in 
an era where aminoglycosides were typically dosed three 
times daily, and, as such, many studies obtained only a 
limited number of samples up to 8 h post infusion. As a 
consequence, the exact influence of obesity on the pharma-
cokinetics of gentamicin, especially clearance, remains yet 
to be quantified across the current body weights that we are 
facing in the clinic.
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definition of morbid obesity). Serum creatinine was meas-
ured and 24-h urine was collected on the study day, with 
which the glomerular filtration rate (GFR) was calculated. 
In addition, serum creatinine-based GFR estimates were 
calculated for each patient using either the CG (using LBW 
for obese and TBW for non-obese individuals, as described 
before [19]) or MDRD formula (de-indexed for body surface 
area [BSA]).
For the population pharmacokinetic analysis, BSA was 
calculated for each individual using the Du Bois–Du Bois 
formula [21]. ABW was calculated with Eq. (1), as published 
previously [12]:
where IBW represents ideal body weight in kg, calculated 
with the Devine formula [22], and TBW represents the TBW 
in kg. When TBW was smaller than IBW, IBW was imputed 
as ABW.
2.3  Drug Assay
Total gentamicin plasma concentrations were quantified 
using a commercially available, validated immuno-assay 
kit (Roche Diagnostics GmbH, Mannheim, Germany). 
The lower limit of quantification (LLOQ) of this assay 
was 0.4 mg/L and the lower limit of detection (LOD) was 
0.3 mg/L.
2.4  Non‑Compartmental Statistical Analysis
Individual gentamicin AUC 24 was calculated using the trap-
ezoidal rule. Cmax and Cmin were defined as the gentamicin 
plasma concentration measured at 1 and 24 h after start of 
infusion, respectively. Categorical data were analyzed by 
Chi-square test. Continuous data are shown as mean ± 
standard deviation (SD) and analyzed by t-test when nor-
mally distributed or as median ± interquartile range (IQR) 
and analyzed by Mann-Whitney–Wilcoxon test when not 
normally distributed. Statistics were performed using R 
(version 3.4.4) [23]. Differences with a p-value < 0.05 were 
considered statically significant.
2.5  Population Pharmacokinetic Analysis 
and Validation
Gentamicin concentrations in both obese and non-obese 
were analyzed using non-linear mixed-effect modelling 
 (NONMEM® version 7.3 [Icon Development Solutions, 
Ellicott City, MD, USA],  Pirana® version 2.9.7, and PsN 
[Perl-speaks-NONMEM] version 4.6.0) [24, 25]. Concentra-
tions below LLOQ (n = 24/280, 8.6%) were incorporated in 
the analysis using the M3 method [26].
(1)ABW = IBW + 0.4 × (TBW − IBW)
Model development was done in three stages: (1) defi-
nition of the structural model; (2) development of the sta-
tistical model; and (3) a covariate analysis. In these steps, 
discrimination between models was made by comparing the 
objective function value (OFV, defined by – 2 log likeli-
hood). A p-value of < 0.05, representing a decrease of 3.84 
in the OFV value between nested models, was considered 
statistically significant. Furthermore, goodness-of-fit plots, 
differences in parameter estimates’ coefficients of variation, 
or individual plots were evaluated to discriminate between 
models. Inter-individual variability on parameter estimates 
was assumed to be log-normally distributed in the popu-
lation. For residual variability, e.g., resulting from assay 
errors, model misspecifications or intra-individual variabil-
ity, a combined additive and proportional error model was 
investigated.
For the covariate analysis, potentially relevant relations 
between covariates and pharmacokinetic parameters were 
visually explored by plotting inter-individual variability 
estimates independently against the individual covariate 
values. Covariates that were explored in this manner were 
TBW, LBW, ABW, BMI, age, sex, GFR, and eGFR (BSA-
corrected MDRD or CG using LBW). After visual inspec-
tion, potential covariates were separately entered into the 
model. Continuous covariates were introduced using Eq. 2 
for exponential relations and Eq. 3 for linear relations:
where Pi and Pp represent individual and population parame-
ter estimates, COV represents the covariate,  COVstandard rep-
resents a population standardized (e.g., 70 kg for TBW) or 
median value for the covariate, X represents the exponent for 
a power function, and Z is the slope parameter for the linear 
covariate relationship. Categorical covariates were entered 
into the model by calculating a separate pharmacokinetic 
parameter for each category of the covariate. If applicable, it 
was evaluated whether the inter-individual variability in the 
parameter concerned decreased upon inclusion of the covari-
ate and whether the plot of the inter-individual variability 
versus the covariate improved. Additionally, goodness of 
fit was assessed as described earlier. Using forward inclu-
sion (p < 0.05, OFV decrease > 3.8) and backward deletion 
(p < 0.001, OFV increase > 10.8), inclusion of the covariate 
in the final model was justified.
Internal model validation was performed using pre-
diction-corrected visual predictive checks (pcVPCs) and 
bootstrap resampling analysis [27, 28]. More details of the 
(2)Pi = Pp ×
(
COV
COVstandard
)X
(3)Pi = Pp ×
(
1 + Z ×
(
COV − COVstandard
))
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methods used for model development and internal valida-
tion can be found in the Electronic Supplementary Material 
(ESM).
2.6  Model‑Based Simulations to Guide Drug Dosing
Using the final model, Monte Carlo simulations were per-
formed in 10,000 patients in a weight range of 50–215 kg 
for different dose regimens, which included 5 and 7 mg/
kg TBW, 5 and 8 mg/kg LBW, 5 mg/kg ABW, and a novel 
dose nomogram based on the final pharmacokinetic model. 
In every simulation, gentamicin was administered intrave-
nously over 30 min with 24 h of follow-up. Values for LBW, 
IBW, and ABW were obtained by resampling data stratified 
on TBW from the National Health and Nutrition Examina-
tion Survey (NHANES) database containing demographic 
data from a large representative cohort of adults from the 
USA from 1999 to 2016 [29]. Simulations aimed to target 
a similar exposure (AUC 24) to that in non-obese individu-
als (< 100 kg) receiving gentamicin in the standard dose 
of 5 mg/kg TBW and non-toxic Cmin values (< 1 mg/L) in 
obese individuals.
3  Results
3.1  Patients and Data
Table 1 shows the patient characteristics of the 20 mor-
bidly obese patients (median body weight 148.8 kg, range 
109–221 kg) and eight non-obese individuals (median body 
weight 72.9 kg, range 53–86 kg) that were included in this 
study. For each individual, ten samples were obtained, yield-
ing 280 gentamicin plasma concentrations in total. Figure 1 
shows the measured plasma concentrations versus time after 
start of infusion. Both AUC 24 and Cmax were lower in mor-
bidly obese individuals administered 5 mg/kg LBW than in 
non-obese individuals administered 5 mg/kg TBW (AUC 24: 
43.7 ± 9.7 vs. 68.7 ± 9.5 mg h/L, p < 0.001; Cmax: 8.6 ± 2.2 
vs. 17.8 ± 2.6 mg/L, p < 0.001). Cmin levels in all individuals 
were < 0.5 mg/L.
3.2  Population Pharmacokinetic Model 
and Validation
A two-compartment model with a combined residual error 
model best described the data, with inter-individual vari-
ability on central volume of distribution (Vc) and clearance 
(Table 2).
The covariate analysis showed that TBW was the most 
predictive covariate for both Vc and clearance (p < 0.001 for 
both). Figure 2 shows the individual estimates for clearance 
and Vc versus TBW of the included obese and non-obese 
individuals. Plots for the other covariates are shown in the 
ESM (Fig. S1). Implementation of TBW with a power func-
tion on Vc and clearance led to a reduction in unexplained 
inter-individual variability from 49.6% to 18.5% for Vc and 
from 32.2% to 17.4% for clearance. In addition, OFV was 
Table 1  Patient characteristics
Data are given as median ± interquartile range [range], unless stated otherwise
BMI body mass index
Characteristic Morbidly obese (n = 20) Non-obese (n = 8) p value
Sex (% male) 50% 50% 1.00
Total body weight (kg) 148.8 ± 25.9 [109–221] 72.9 ± 7.9 [53–86] < 0.001
Lean body weight (kg) 76.5 ± 25.4 [55–99] 54.0 ± 17.9 [37–68] 0.003
BMI (kg/m2) 44.4 ± 8.3 [37–65] 21.8 ± 2.2 [18–24] < 0.001
Age (years) 40.5 ± 12.5 [19–54] 22.0 ± 3.5 [19–50] 0.004
Glomerular filtration rate 
(mL/min)
171.9 ± 70.0 [110–230] 123.7 ± 54.8 [91–170] 0.013
Gentamicin dose (mg) 380 ± 120.0 [280–480] 360 ± 30.0 [240–440] 0.466
Fig. 1  Observed gentamicin plasma concentrations (mg/L) versus 
time after start of infusion (h) for morbidly obese (receiving 5  mg/
kg lean body weight, black lines) and non-obese (receiving 5 mg/kg 
total body weight, grey lines) individuals. Each line represents one 
individual
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found to reduce by 44.4 (p < 0.001) and 30.2 (p < 0.001) 
points for Vc and clearance, respectively. Implementation of 
LBW or ABW on Vc was inferior to TBW, even though these 
covariates significantly improved the base model as well, 
albeit less convincingly than TBW, with smaller OFV drops 
(– 19.1 and – 17.3 for LBW on Vc and clearance, – 18.8 
and – 21.2 for ABW on Vc and clearance, respectively) and 
poorer goodness-of-fit diagnostics (data not shown). While 
no influence of MDRD or CG was visible, GFR seemed to 
Table 2  Population 
pharmacokinetic parameters of 
the base model and final model
Parameter estimates are shown with standard error of estimate reported as %CV
CI confidence interval, CL clearance from the central compartment, CL70 kg clearance from the central com-
partment for an individual weighing 70 kg, CV coefficient of variation, IIV inter-individual variation, OFV 
objective function value, Q intercompartmental clearance, TBW total body weight, Vc central volume of 
distribution, Vc70 kg central volume of distribution for an individual weighing 70 kg, Vp peripheral volume of 
distribution, X exponent for a power function on Vc, Z exponent for a power function on CL
a Eta-shrinkage for IIV in the final model is 4% (CL) and 7% (Vc)
b Estimates of residual error terms are reported as standard deviation
Parameter Base model (%CV) Final model (%CV) Bootstrap final model 
(n = 939/1000 successful runs) 
[mean (95% CI)]
Vc (L) 23.3 (10.0)
Vc = Vc70 kg × (TBW/70)X
 Vc70 kg (L) 11.9 (8.8) 11.9 (10.3–13.5)
 X 1.25 (10.8) 1.26 (1.06–1.46)
CL (L/min) 0.130 (5.7)
CL =  CL70 kg × (TBW/70)Z
 CL70 kg (L/min) 0.0892 (5.6) 0.0892 (0.0815–0.0969)
 Z 0.729 (9.6) 0.735 (0.572–0.898)
Vp (L) 7.06 (8.0) 7.29 (5.7) 7.33 (6.32–8.35)
Q (L/min) 0.0812 (17.4) 0.0848 (8.2) 0.0873 (0.0541–0.121)
IIV (%)
 Vca 49.6 (11.6) 19.2 (16.6) 18.9 (7.98–25.7)
 CLa 32.0 (16.4) 18.1 (5.0) 17.6 (11.3–22.2)
 Covariance IIV Vc–CL 0.0316 0.0302 (0.00894–0.0514)
Proportional  errorb 0.156 (10.8) 0.159 (8.2) 0.157 (0.125–0.190)
Additive error (mg/L)b 0.221 (10.2) 0.206 (8.4) 0.204 (0.160–0.247)
OFV 329.4 232.9 223.0
Fig. 2  Individual values (n = 28) for a central volume of distribution 
(in L) and b clearance (in L/min) versus total body weight from the 
base model. The black line represents the covariate relation as imple-
mented in the final model (Table 2). CL clearance, TBW total body 
weight, Vc central volume of distribution
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slightly influence clearance, although this correlation disap-
peared after inclusion of TBW on clearance.
According to the final model (Table 2), Vc and clearance 
are best described using Eqs. (4) and (5):
where  Vc,i and  CLi are the Vc and clearance of the ith indi-
vidual, respectively.  TBWi is the TBW of the ith individual. 
95% confidence intervals (CIs) based on the bootstrap resa-
mpling (Table 2) are shown in brackets.
The parameter estimates of the final model are shown in 
Table 2. Goodness-of-fit plots of the final model are pre-
sented in the ESM (Fig. S2).
For internal validation, stratified pcVPCs for obese and 
non-obese individuals are shown in Fig. 3 and show good 
predictive performance for both groups where CIs for the 
median and 2.5th and 97.5th percentiles of observed and 
model-simulated data are in good agreement. The results of 
the bootstrap analysis confirmed the model parameters and 
robustness of the model and are presented in Table 2.
(4)Vc,i = 11.9[10.3−13.5] ×
(
TBW
i
∕70
)1.25[1.06−1.46]
(5)
CL
i
= 0.089[0.082− 0.097] ×
(
TBW
i
∕70
)0.73[0.57− 0.90]
3.3  Model‑Based Simulations with Different Dose 
Regimens
Figure 4 shows the median and 95% CI for the AUC 24 (upper 
panel) and Cmin (lower panel) with different dosing regimens 
for individuals with a weight range of 50–215 kg based on 
Monte Carlo simulations. The median AUC 24 in non-obese 
individuals (< 100 kg) receiving gentamicin at a commonly 
prescribed dose of 5 mg/kg TBW represents the target for 
gentamicin exposure (depicted as horizontal dashed line.
Figure 4 (upper panel) illustrates that a dose based on 
LBW (i.e., 5 or 8 mg/kg LBW) leads to a decrease in AUC 
24 with increasing body weight. In contrast, dosing based on 
TBW (depicted for 5 and 7 mg/kg) leads to higher AUC 24 
values with increasing body weight. The use of ABW (5 mg/
kg) results in a similar AUC 24 across body weights as that of 
the reference < 100 kg group, with a slight trend towards a 
decreased AUC 24 with increasing body weight. When a dose 
regimen based the equation for clearance of the final model 
[i.e., an allometric ‘dose weight’, which is calculated as 70 
× (TBW/70)0.73; Table 3] is used, a similar AUC 24 to that 
of the reference group is yielded across all weight ranges 
up to 215 kg.
Fig. 3  Prediction-corrected visual predictive checks of the final 
model for non-obese (upper left panel) and obese (upper right panel) 
individuals. The observed concentrations are shown as black circles; 
the median and 2.5th and 97.5th percentiles of the observed data are 
shown as the solid and lower and upper dashed lines, respectively. 
The gray shaded areas show the 95% confidence intervals of the 
median (dark gray) and 2.5th and 97.5th percentiles (light gray) of 
the simulated concentrations (n = 1000) based on the original data-
set. Lower panels show the observed proportion below the limit of 
quantification (black dots), where shaded areas represent the 95% 
confidence interval of the proportion based on the simulated concen-
trations (n = 1000). LOQ limit of quantification
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For all dose regimens and weight ranges, gentamicin Cmin 
values were below the limit of 1 mg/L (Fig. 4, lower panel). 
Results for Cmax are shown in Fig. S3 in the ESM, showing 
that a TBW-based dose regimen yields similar Cmax values 
across body weights.
4  Discussion
In this study, we have successfully developed a popula-
tion pharmacokinetic model for gentamicin based on full 
pharmacokinetic curves obtained in individuals with body 
weights ranging from 53 to 221 kg. Our study shows that 
in obese individuals, both gentamicin clearance and Vc are 
significantly influenced by body weight. These findings can 
be used as guide for dosing in the ever-increasing group of 
obese and morbidly obese patients.
Fig. 4  Boxplots (median and 95% confidence interval) represent-
ing gentamicin AUC 24 (upper panel) and Cmin  (lower panel) for dif-
ferent weight categories based on Monte Carlo simulations with six 
different TBW-, LBW- (calculated with the Janmahasatian formula 
[18]), and ABW [calculated as IBW + 0.4  ×  (TBW – IBW)]-based 
dosing regimens (n = 10,000 per regimen). The proposed nomogram 
is based on a ‘dose weight’ calculated as 70 × (TBW/70)0.73 (shown 
in Table 3). The dashed line represents the median value of 5 mg/kg 
TBW in the < 100 kg group as a target reference for AUC 24 (upper 
panel) or 1  mg/L as a target reference for Cmin (lower panel). ABW 
adjusted body weight, AUC 24 area under the concentration–time 
curve from time zero to 24 h, Cmin minimum (trough) concentration, 
LBW lean body weight, TBW total body weight
Table 3  Proposed dose nomogram [based on a 5  mg/kg ‘dose 
weight’, calculated as 70 × (TBW/70)0.73] for selecting the gentamicin 
dose in obese individuals with normal renal function (> 60 mL/min)
TBW total body weight
TBW (kg) Gentamicin dose (mg)
< 100 Dose on TBW
100–120 480
120–140 560
140–160 600
160–180 680
180–200 760
200–220 800
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Our study shows that gentamicin clearance increases with 
TBW. From the studies investigating the pharmacokinetics 
of aminoglycosides in obesity [12, 14–17, 30, 31], four 
papers reported an increase in clearance in obese patients 
[12–14, 16] and two studies found ABW as a predictive 
covariate [13, 14]. In these studies participants were only 
moderately obese (average body weights around 80–100 kg 
with SDs around 15–20 kg). Moreover, at the time these 
studies were conducted, aminoglycosides were typically 
dosed in regimens of up to three times daily, and as such 
many studies obtained samples up to 8 h post infusion only, 
thereby limiting the estimation of gentamicin clearance and 
the prediction of 24-h exposure and Cmin values. In this 
respect, we believe that our study is an important addition 
to the existing literature, since we were able to sample up 
to 24 h post infusion (instead of 8 h) in a wide range of 
body weights (53–221 kg) and, combined with using state-
of-the-art modelling techniques, we could for the first time 
accurately assess gentamicin clearance and its covariates in 
the obese population.
An important question is how the finding that clear-
ance changes with body weight in obese individuals can 
be explained. The exponent of 0.73 (95% CI 0.57–0.90) 
we identified for the change with weight is comparable to 
the value of 0.75 which has been reported as a value that 
describes the influence of size on clearance in allometry 
theory [32]. However, it is debatable whether an increase 
in weight resulting from obesity can be compared with an 
increase in weight because of an increase in size [32]. For 
other drugs that were studied in obese patients, many show 
unchanged clearance with increasing weight, even when 
morbidly obese patients were included [33–35]. The increase 
in gentamicin clearance with body weight we identify in 
this study could potentially be explained by a larger GFR in 
obese individuals and/or an increase in organic cation trans-
porter 2 (OCT2) activity as gentamicin was reported to be a 
substrate for OCT2 [36]. With respect to GFR, it is empha-
sized that in our study only individuals with a GFR > 60 mL/
min were included. In our study, weight was the most impor-
tant covariate, and after implementation of weight, no addi-
tional influence of GFR could be identified, even though the 
GFR range in our population was large (110–230 mL/min). 
While this does not preclude GFR being the explanation for 
the observed increase in gentamicin clearance in the obese, 
and also for other renally excreted drugs such as cefazoline, 
no increase in clearance with increasing weight was found 
when studied in morbidly obese and non-obese individuals 
[35, 37]. As such, perhaps the increased activity in OCT2 
that was reported in overfed rats and that led to increased 
gentamicin uptake in renal tubular cells [36] may be con-
sidered as an explanation for the findings of our study. In 
line with this hypothesis, for metformin, which is known 
to be secreted by OCT2 in the tubulus, a larger clearance 
was found in obese adolescents (1.17 L/min) than in non-
obese children (0.55 L/min), which was also explained by 
a higher OCT2-mediated tubular secretion of metformin in 
obese individuals [38]. From these results it seems that more 
basic research is needed to identify the exact cause of our 
findings.
Furthermore, our study demonstrates that Vc best corre-
lates with body weight. Earlier studies with aminoglycosides 
in obese patients found ABW or LBW to correlate with vol-
ume of distribution [12–14, 17, 30]. In our study we obtained 
a large number of samples over a 24-h window, including 
samples that were taken shortly after infusion (i.e., 5, 30, 60, 
and 90 min after infusion). This study design allows us to 
fully describe the pharmacokinetics of gentamicin in detail. 
Most of the previously published studies were performed 
with sparse (therapeutic drug monitoring) data with only a 
few samples taken shortly after infusion and consequently 
analyzed by non-compartmental analysis, thereby complicat-
ing exact estimation of the volume of distribution. While the 
detailed information resulting from our sampling scheme 
and advanced modelling strategy justifies the conclusions 
regarding changes of volume of distribution with weight, 
the results challenge the common assumption that only lim-
ited changes in volume of distribution are to be expected for 
hydrophilic drugs such as gentamicin. It therefore seems 
that lipophilicity alone is a poor predictor of how volume 
of distribution changes with increasing body weight, as was 
demonstrated in several recent reviews [9, 39].
Based on the results of our study, we propose admin-
istration of gentamicin using a practical dose nomogram 
(Table 3) that is based on a body weight-derived allomet-
ric ‘dose weight’ [i.e., 70 × (TBW/70)0.73] and is derived 
from the allometric relationship between clearance (driving 
AUC) and TBW (Table 2, Eq. 5). Considering fAUC 24/MIC 
as the primary pharmacodynamic index for aminoglycoside 
treatment, our dosing nomogram yields a similar gentamicin 
exposure (AUC 24) across all weights with all Cmin values 
< 1 mg/L (Fig. 4). In clinical practice, the nomogram can 
easily be implemented to select the initial gentamicin dos-
age, after which dose individualization may be employed 
by estimating the individual’s gentamicin clearance. This 
is typically done using therapeutic drug monitoring (where 
one or two samples are taken during the β-elimination phase, 
for instance between 2 and 8 h post infusion) in combination 
with Bayesian software employed with a suitable population 
pharmacokinetic model. The population pharmacokinetic 
model presented in the current paper could be used for this 
purpose. Alternatively, for example when such software is 
unavailable, other approaches have been suggested to indi-
vidualize gentamicin drug treatment [7].
Figure  4 also illustrates that ABW- and LBW-based 
dose regimens show trends towards a lower exposure with 
increasing body weight. Despite these trends across weight, 
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it seems that 8 mg/kg LBW and 5–6 mg/kg ABW could be 
considered as alternatives for our nomogram because using 
these doses in the median range of the morbidly obese popu-
lation leads to rather similar AUC 24 values. Implementation 
of LBW, and to a lesser extend ABW, has, however, been 
hampered by the complexity of the calculations, which is 
why we came up with our nomogram, as depicted in Table 3.
Some limitations may apply to our results. First, indi-
viduals in our study were, besides (some) being over-
weight, otherwise healthy, relatively young, and had no 
renal impairment. As a consequence, renal dysfunction in 
the obese could not be studied, while in non-obese patients 
gentamicin clearance has been reported to be dependent on 
renal function [40]. Also, drug pharmacokinetics have been 
shown to be influenced by critical illness [41]. Therefore, 
further refinement of our model is warranted for use in obese 
patients with renal impairment, critical illness, and/or older 
age. Still, we believe that the dose recommendations from 
the current study can be a valuable starting point for dosing 
of obese patients with renal impairment or critical illness. 
Second, in the current study we did not study the pharma-
cokinetics of gentamicin after significant reduction in body 
weight following bariatric surgery. It has been shown for 
the benzodiazepine midazolam that the pharmacokinetics 
in these individuals are different to those in individuals with 
the same body weight without a history of obesity [42]. 
Third, we did not include individuals with a BMI 25–35 kg/
m2. However, based on the relationship between TBW and 
clearance and Vc, as depicted in Fig. 2, we think it is justi-
fied to conclude that the pharmacokinetics will not be any 
different in these individuals. Last, the obese individuals in 
our study underwent bariatric surgery during the study pro-
cedures, which in theory might influence pharmacokinetics. 
In our hospital, bariatric surgery is performed laparoscopi-
cally, with a short procedure (usually 30–45 min) involving 
minimal blood loss (usually < 50 mL). Also, hemodynam-
ics were tightly monitored and regulated during surgery. 
No major hemodynamic instability was recorded for any of 
the included individuals in our study. For this reason, we 
expect that the influence of surgery on the pharmacokinetics 
is negligible.
5  Conclusion
We show that gentamicin clearance increases with body 
weight according to a power function with an exponent of 
0.73. As we found that the current worldwide deployed dos-
ing strategy of dosing on LBW or ABW may lead to lower 
exposure with increasing bodyweight, we propose the use of 
a dose nomogram on an allometric ‘dose weight’ [calculated 
as 70 × (TBW/70)0.73; Table 3] for dosing gentamicin in 
(morbidly) obese patients > 100 kg to obtain similar expo-
sure across all body weights up to 215 kg.
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